Corporate

What they say about us: the Italian press talks about the investment plan of IBSA Farmaceutici, aimed at promoting the Company’s continuous growth within the Italian pharmaceutical sector

The commitment of IBSA Farmaceutici, the value and the importance of its activities for the patients, and the Company’s contribution to the Country: these are the main topics taken up and analyzed by the national and industry press following the meeting Innovazione, investimenti e ricerca: le sfide di IBSA in Italia (“Innovation, investments and research: IBSA’s challenges in Italy”), which was held last June 15. A media echo that has given visibility to IBSA’s efforts – in the different areas of research, development, production and sustainability – despite the troubles of a difficult period, such as that of the most acute phase of the pandemic, but thanks to which the Company has acquired the awareness of being able to continue to grow and stand out as an important reference for patients, as well as a successful example of the quality of the Made in Italy research and production worldwide.

 

IBSA’s contribution to the Country’s health system has been an important – and much appreciated – sign, whose importance has been highlighted by some media, also with a view to restarting the economy and continuing to grow the Italian pharmaceutical sector. Here is a small selection of articles have dedicated an in-depth analysis to IBSA’s activities, touching on several highly topical insights and issues.

IBSA’s role and objectives in Italy have been told on the online portal of Fortune Italia, also in light of the € 15 million investment plan that the Company is carrying out in order to implement production, acquire cutting-edge machinery and restructure its Lodi headquarters, within a greener and more sustainable perspective.

In fact, IBSA has never stopped, not even in the face of the crisis generated by the global pandemic and, in an interview with Aboutpharma, CEO and Managing Director Luca Crippa spoke of the trust IBSA has long been placing in our Country, investing in Italy every year 7% of its turnover in research and development.  

During the June press meeting, together with Dr. Crippa, Andrea Giori - Head of Research & Development - completed the narration on IBSA’s commitment to research and development explaining the importance of offering the patient “drugs in the best form”. In his interview with the Askanews agency, he thoroughly analyzed the key concept: working on already known active ingredients in order to obtain formulations that improve adherence to therapy, therefore benefitting patients and improving their compliance.

Engineering molecules to develop better formulations is one of the main characteristics that differentiate and distinguish IBSA within the scenario in which the Company operates. Luca Crippa emphasized this concept to Pharmastar, highlighting how this constant commitment to research and innovation allows the company to export the “Made in Italy of excellence” all over the world.

IBSA operates in 10 therapeutic areas, with a particular focus on some of these, as Andrea Giori told Pharmastar. The Company, indeed, is particularly focused on Endocrinology, Medically Assisted Procreation, the Osteoarticular area and Dermoaesthetic Medicine, all areas where IBSA boasts some significant innovations.